Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounjaro and Zepbound, and raised its revenue guidance amid sustained demand despite pricing pressures. Novo, holding 38.8% market share, also beat expectations but faced investor concerns over its pipeline and growth prospects, especially after mixed trial results and a weaker-than-expected launch of its Wegovy pill. The diverging investor confidence highlights Lilly as the market momentum leader, while Novo works to regain market share and prove its long-term growth strategy.
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progressio...
